Eureka Therapeutics, Inc.
53 articles about Eureka Therapeutics, Inc.
-
Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers
4/2/2024
Eureka Therapeutics, Inc. today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).
-
Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy
3/18/2024
Eureka Therapeutics, Inc. today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).
-
Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer
6/6/2023
Eureka Therapeutics, Inc. today announced that the California Institute for Regenerative Medicine (CIRM) awarded the Company a $10.6 million grant to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of pediatric patients with refractory/relapsed liver cancer.
-
Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute
3/14/2023
Eureka Therapeutics, Inc. today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka’s proprietary ARTEMIS ® T-cell receptor platform.
-
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma
10/18/2022
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS ® T Cell Therapy for Neuroblastoma.
-
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS® T cells
10/17/2022
Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ET140203 for the treatment of hepatoblastoma (HB), a rare childhood tumor in the liver that typically occurs in children under the age of 5.
-
Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma
9/29/2022
Eureka Therapeutics, Inc. announced the publication of a study in the New England Journal of Medicine entitled “GPRC5D-Targeted CAR T Cells for Myeloma.” The study was led by Dr. Eric Smith of the Dana-Farber Cancer Institute, Dr. Renier Brentjens of the Roswell Park Comprehensive Cancer Center, and Dr. Sham Mailankody of the Memorial Sloan Kettering Cancer Center.
-
Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer
8/3/2022
Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a study in Nature’s Scientific Reports entitled “ Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma ”.
-
Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80
6/6/2022
Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a preclinical study in blood entitled “ A TCR Mimic CAR T Cell Specific for NDC80 Is Broadly Reactive With Solid Tumors and Hematological Malignancies ”.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS® T Cells (ECT204) for Advanced Liver Cancer
5/31/2022
Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS ® T Cells (ECT204) for Advanced Liver Cancer.
-
Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference and Expo
4/25/2022
Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference and Expo.
-
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ARTEMIS® T Cells
2/8/2022
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ARTEMIS ® T Cells.
-
Eureka Therapeutics Announces Initiation of Phase I/II ARYA-2 Clinical Trial of ET140203 ARTEMIS® T Cells to Treat Pediatric Liver Cancer
11/17/2021
Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced the initiation of ARYA-2, a Phase I/II open-label, dose escalation clinical trial of ET140203 ARTEMIS® T-cell therapy in pediatric patients with relapsed or refractory hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS), or hepatocellular carcinoma (HCC).
-
Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
11/1/2021
Imugene Ltd and Eureka Therapeutics, Inc. today announced a strategic collaboration to evaluate Imugene’s CD19 oncolytic virus onCARlytics technology in combination with Eureka’s anti-CD19 ARTEMIS® T-cell therapy for the treatment of solid tumours.
-
Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer
7/21/2021
Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.
-
This morning, multiple companies announced clinical and strategic collaborations to develop novel therapies and treatments for various diseases. Here are some of them.
-
Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma
7/6/2021
Eureka Therapeutics, Inc. announced today that Eureka and Memorial Sloan Kettering Cancer Center (MSK) entered into a license agreement with Sanofi for the non-CAR use of a novel, human binding domain targeting GPRC5D (G Protein-Coupled Receptor Family C Group 5 Member D).
-
With billions invested in R&D over the past year to find vaccines and therapies for the novel coronavirus, a few select life sciences companies and academic institutions are working on the hypothesis that intranasal vaccines and therapies could be key to stopping COVID-19 in its tracks, and provi...
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.